NASDAQ:SBBP

Strongbridge Biopharma Stock Forecast, Price & News

$2.64

+0.01 (+0.38 %)

(As of 04/12/2021 08:58 AM ET)

Add

Compare

Today's Range

$2.64

Now: $2.64▼

$2.64

50-Day Range

$2.61

MA: $3.02▼

$3.62

52-Week Range

$1.86

Now: $2.64▼

$4.63

Volume200 shs

Average Volume1.08 million shs

Market Capitalization$178.32 million

P/E RatioN/A

Dividend YieldN/A

Beta1.91

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical trials for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that has completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:SBBP

Previous Symbol

CUSIPN/A

CIK1634432

Webwww.strongbridgebio.com

Phone610-254-9200

Employees72

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.10

Current Ratio4.51

Quick Ratio4.45

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$21.71 million

Price / Sales8.21

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.33 per share

Price / Book1.98

Profitability

EPS (Most Recent Fiscal Year)($1.10)

Net Income$-49,450,000.00

Net Margins-149.79%

Return on Equity-65.85%

Return on Assets-38.81%

Miscellaneous

Outstanding Shares67,545,000

Market Cap$178.32 million

Next Earnings Date5/5/2021 (Estimated)

OptionableOptionable

Headlines

Strongbridge's Recorlev Shows Improvements in Cortisol Control In Cushing's Syndrome, Diabetes
April 8, 2021 | finance.yahoo.com

Strongbridge Biopharma plc Announces Publication of Diabetes Subgroup Analysis from Phase 3 SONICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome in Frontiers in Endocrinology
April 7, 2021 | finance.yahoo.com

Analysts Expect Strongbridge Biopharma plc (NASDAQ:SBBP) Will Post Quarterly Sales of $8.22 Million
March 27, 2021 | americanbankingnews.com

Zacks: Analysts Anticipate Strongbridge Biopharma plc (NASDAQ:SBBP) to Post -$0.10 Earnings Per Share
March 26, 2021 | americanbankingnews.com

Strongbridge Gains on Results
March 22, 2021 | baystreet.ca

Strongbridge Biopharma plc Presents Detailed Results from Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2021 Annual Meeting of the Endocrine Society (ENDO)
March 20, 2021 | finance.yahoo.com

Strongbridge Biopharma plc Presents Detailed Results from Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushingâs Syndrome at the 2021 Annual Meeting...
March 20, 2021 | markets.businessinsider.com

Strongbridge Biopharma plc to Present at Oppenheimer’s 31st Annual Healthcare Conference
March 15, 2021 | finance.yahoo.com

Strongbridge Biopharma plc to Present at Oppenheimer's 31st Annual Healthcare Conference
March 15, 2021 | feeds.benzinga.com

Strongbridge Biopharma plc (NASDAQ:SBBP) Analysts Are Pretty Bullish On The Stock After Recent Results
March 5, 2021 | finance.yahoo.com

Strongbridge Biopharma files new drug application with FDA for rare disease therapy
March 3, 2021 | bizjournals.com

Recap: Strongbridge Biopharma Q4 Earnings
March 3, 2021 | benzinga.com

Strongbridge Biopharma: Q4 Earnings Snapshot
March 3, 2021 | finance.yahoo.com

Strongbridge Biopharma plc Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update
March 3, 2021 | finance.yahoo.com

Preview: Strongbridge Biopharma's Earnings
March 2, 2021 | benzinga.com

Strongbridge Biopharma plc Announces Submission of New Drug Application for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome to the U.S. Food & Drug Administration
March 2, 2021 | finance.yahoo.com

Strongbridge Biopharma plc to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call on March 3, 2021
February 25, 2021 | finance.yahoo.com

12 Health Care Stocks Moving In Monday's After-Market Session
January 6, 2021 | benzinga.com

Strongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update
January 6, 2021 | finance.yahoo.com

Is Strongbridge Biopharma (NASDAQ:SBBP) Using Debt Sensibly?
January 4, 2021 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.45 out of 5 stars

Medical Sector

577th out of 2,011 stocks

Pharmaceutical Preparations Industry

271st out of 772 stocks

3.5 Analyst's Opinion

Consensus Rating
Strongbridge Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.00, Strongbridge Biopharma has a forecasted upside of 166.2% from its current price of $2.63.
Amount of Analyst Coverage
Strongbridge Biopharma has only been the subject of 1 research reports in the past 90 days.

2.3 Community Rank

Outperform Votes
Strongbridge Biopharma has received 311 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Strongbridge Biopharma has received 369 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Strongbridge Biopharma has received 54.26% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Strongbridge Biopharma and other stocks. Vote “Outperform” if you believe SBBP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SBBP will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Strongbridge Biopharma does not currently pay a dividend.
Dividend Growth
Strongbridge Biopharma does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Strongbridge Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.60% of the stock of Strongbridge Biopharma is held by insiders.
Percentage Held by Institutions
58.27% of the stock of Strongbridge Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Strongbridge Biopharma are expected to grow in the coming year, from ($0.75) to ($0.56) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Strongbridge Biopharma is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Strongbridge Biopharma is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Strongbridge Biopharma has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$2.64

+0.01 (+0.38 %)

(As of 04/12/2021 08:58 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive SBBP News and Ratings via Email

Sign-up to receive the latest news and ratings for SBBP and its competitors with MarketBeat's FREE daily newsletter.

Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions

Is Strongbridge Biopharma a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Strongbridge Biopharma stock.
View analyst ratings for Strongbridge Biopharma or view top-rated stocks.

What stocks does MarketBeat like better than Strongbridge Biopharma?

Wall Street analysts have given Strongbridge Biopharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Strongbridge Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Strongbridge Biopharma's next earnings date?

Strongbridge Biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Strongbridge Biopharma.

How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) issued its earnings results on Tuesday, March, 2nd. The biotechnology company reported ($0.11) EPS for the quarter, topping the Zacks' consensus estimate of ($0.12) by $0.01. Strongbridge Biopharma had a negative trailing twelve-month return on equity of 65.85% and a negative net margin of 149.79%.
View Strongbridge Biopharma's earnings history.

How has Strongbridge Biopharma's stock been impacted by COVID-19?

Strongbridge Biopharma's stock was trading at $2.32 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SBBP shares have increased by 13.4% and is now trading at $2.63.
View which stocks have been most impacted by COVID-19.

What guidance has Strongbridge Biopharma issued on next quarter's earnings?

Strongbridge Biopharma updated its FY 2021 Pre-Market earnings guidance on Wednesday, March, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $34-36 million, compared to the consensus revenue estimate of $35.81 million.

What price target have analysts set for SBBP?

3 brokerages have issued 12-month price objectives for Strongbridge Biopharma's stock. Their forecasts range from $5.00 to $10.00. On average, they anticipate Strongbridge Biopharma's stock price to reach $7.00 in the next year. This suggests a possible upside of 166.2% from the stock's current price.
View analysts' price targets for Strongbridge Biopharma or view top-rated stocks among Wall Street analysts.

Who are Strongbridge Biopharma's key executives?

Strongbridge Biopharma's management team includes the following people:

Mr. John H. Johnson, CEO & Director (Age 63, Pay $1.13M)
Dr. Fredric Cohen, Chief Medical Officer (Age 56, Pay $784.11k)
Mr. Richard S. Kollender CPA, M.B.A., CPA, Pres & CFO (Age 52)
Dr. Per Marin M.D., Ph.D., Founder and Sr. Clinical Advisor
Mr. Peter J. Valentinsson, Sr. VP of Global Technical Operations
Mr. Stephen J. Long, Chief Legal Officer & Company Sec. (Age 55)
Mr. Brian Conner, Chief Compliance Officer
Mr. Dave Bonnell, Sr. VP of Sales
Ms. Emily Doyle, Chief HR Officer
Mr. Scott L. Wilhoit, Chief Commercial Officer (Age 58)

Who are some of Strongbridge Biopharma's key competitors?

Some companies that are related to Strongbridge Biopharma include OrganiGram (OGI), BELLUS Health (BLUSF), Calliditas Therapeutics AB (publ) (CALT), Emisphere Technologies (EMIS), Gossamer Bio (GOSS), Bicycle Therapeutics (BCYC), Clovis Oncology (CLVS), IDEAYA Biosciences (IDYA), KalVista Pharmaceuticals (KALV), Xenon Pharmaceuticals (XENE), Kadmon (KDMN), Albireo Pharma (ALBO), Chinook Therapeutics (KDNY), Magenta Therapeutics (MGTA) and Evolus (EOLS).
View all of SBBP's competitors.

What other stocks do shareholders of Strongbridge Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Strongbridge Biopharma investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Energy Transfer (ET), Selecta Biosciences (SELB), Rigel Pharmaceuticals (RIGL), Agile Therapeutics (AGRX), Dicerna Pharmaceuticals (DRNA), Dynavax Technologies (DVAX) and Matinas BioPharma (MTNB).

What is Strongbridge Biopharma's stock symbol?

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

How do I buy shares of Strongbridge Biopharma?

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Strongbridge Biopharma's stock price today?

One share of SBBP stock can currently be purchased for approximately $2.63.

How much money does Strongbridge Biopharma make?

Strongbridge Biopharma has a market capitalization of $177.64 million and generates $21.71 million in revenue each year. The biotechnology company earns $-49,450,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis.

How many employees does Strongbridge Biopharma have?

Strongbridge Biopharma employs 72 workers across the globe.

What is Strongbridge Biopharma's official website?

The official website for Strongbridge Biopharma is www.strongbridgebio.com.

Where are Strongbridge Biopharma's headquarters?

Strongbridge Biopharma is headquartered at 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053.

How can I contact Strongbridge Biopharma?

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]

This page was last updated on 4/12/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here